This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Market Preview: Consider Yourself Warned

Other companies reporting on Tuesday are ADTRAN (ADTN), EXFO (EXFO), and Yum! Brands (YUM)

The economic calendar is light again on Tuesday, headlined by the National Federation of Independent Business small business sentiment survey for September at 7 a.m. ET. The consensus estimate is for a tick up to 93.3 reading from 92.9 last time around. There will also be some data on retail sales with Johnson Redbook's weekly index just before 9 a.m. ET and the ICSC-Goldman Sachs weekly chain-store index due at 7:45 a.m. ET.

Jim O'Sullivan, chief U.S. economist at High Frequency Economics, thinks the NFIB survey could come in shy of expectations.

"We expect a pause after last month's 1.7 point rise; a reversal of some of August's gains has already been reported for the two labor components," he noted in commentary released late Monday. O'Sullivan is looking for a minimal tick up to an even 93.0 in the index, which he notes is derived from 10 components.

With technology a big headwind again on Monday, the action in Apple (AAPL) gets more and more worrisome and it's sure to be market mover for the rest of the week.

An announcement about an iPad Mini may reportedly come this week, and contrary to the run-up ahead of the iPhone 5's launch, the stock has been beat-up of late. Monday's close at $638.17 was the stock's first finish below $640 since mid-August, and it's now down 9.5% since hitting an all-time high of $705.07 on Sept. 21. In after-hours action, Apple dipped down as low as $635.25.

And finally, a big mover after Monday's closing bell was Edwards Lifesciences (EW). The Irvine, Calif.-based heart valve maker gave a weak outlook for the third quarter, citing the impact of austerity measures in Europe and other factors.

The company expects sales of $448 million in the September-ended quarter, below its previous targeted range of between $465 million to $485 million. Edwards said transcatheter heart valve sales were "below expectations" for the quarter, with "global sales estimated at $124 million, including U.S. sales of $55 million." Wall Street's consensus estimate is for revenue of $476.6 million in the quarter.

The stock was last quoted at $90.50, down nearly 16%, on late volume of just below 400,000, according to Nasdaq.com.

-- Written by Michael Baron in New York.



>To contact the writer of this article, click here: Michael Baron.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.
3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs